Schering-Plough's Melanoma Trial Gets Promising Results

Schering-Plough received positive findings with its Phase III trial studying long-term treatment with pegylated interferon alfa-2b in stage III melanoma patients.

Results from the randomized trial showed an 18 percent reduction in the risk of recurrence or death for the drug treatment arm and a four-year relapse-free survival (RFS) rate of 46 percent. An observation arm showed an RFS rate of 39 percent, according to Shering-Plough.

The trial was led by the European Organization for Research and Treatment of Cancer.